Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that it will present a poster at AHA 2024 highlighting Phase 1a data for its lead asset TX000045 ("TX45"), a long-acting, relaxin. TX45 is being developed as a potential best-in-class therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF"). Tectonic announced topline results from the study on September 19, 2024.

AHA 2024 Presentation Details (being held in Chicago, IL, Nov 16-18, 2024):

• Title: The tolerability, safety, pharmacokinetics, and pharmacodynamics of TX000045, a long-acting Fc-relaxin fusion protein after single doses in healthy volunteers
• Presentation ID #: Sa4169
• Presenter: Marcella K. Ruddy, MD, Chief Medical Officer
• Session: A Medley of All Things Pulmonary Hypertension
• Session Date: November 16, 2024
• Session Time: 2:00 PM to 3:00 PM CDT / 3:00 PM to 4:00 PM EDT